AdMeTech Foundation strives to create a national model of prostate care. With a focus on early detection and prevention, we seek to give voice to men with prostate cancer and men at risk.
Since our founding, we have worked with other advocacy groups to influence national and state policy to fight prostate cancer through research and education. AdMeTech’s groundbreaking programs are supported by leaders of medicine, industry, advocacy, government agencies, U.S. Congress, American College of Radiology, Society of Nuclear Medicine and other professional organizations. Our work has been covered by the major media and received commendations from the Massachusetts Governor, the Massachusetts State House and the Boston City Council.
For more information about our education programs, visit our Awareness page.
Our annual Prostate Cancer Awareness Day has expanded and solidified a Massachusetts model of national leadership in recognizing prostate cancer as a public health priority and major area of health care disparity. This event has resulted in the rapidly growing support for increased research funding for the advancement of early diagnosis of prostate cancer among key State legislators.
To view more of AdMeTech’s advocacy accomplishments, click here.
To view samples of formal recognition from Massachusetts leaders, click here.
Recent Selected Accomplishments:
March 2010: US House Oversight and Government Reform Committee held a hearing on prostate cancer diagnostics in March 2010. As a result of this hearing, Representative Elijah Cummings (D-MD) introduced the $650 million Prostate Research Imaging and Men’s Education (PRIME) Act.
Fiscal Year 2010: National Cancer Institute (NIH) increased research funding for prostate imaging by over 20% in 2010 when general funding for prostate cancer research only increased by 2%.
September 1, 2011: The White House Proclamation of the National Prostate Cancer Awareness Month for the first time in its history recognized and cited the importance of research to advance early detection, including prostate imaging and biomarkers.
September 15, 2011: AdMeTech’s Prostate Cancer Awareness Day at the Massachusetts State House created a Massachusetts model of national leadership when Senate President and Speaker of the House introduced legislation recognizing prostate cancer as a public health priority, central issue in men’s health and a major health disparity area – and issued a call to action to improve diagnostic tools for early detection and treatment.
October 2011 – May 2012: Rapidly growing number of the leaders of the US Congress support the $650 million AdMeTech-driven PRIME Act and related prioritization of government investment in the advancement of diagnostic tools, including imaging and novel biomarkers. The PRIME Act was introduced as the result of the March 2010 Congressional Hearing by the US House Oversight and Government Reform Committee which framed the need to improve diagnostic tools for prostate cancer and featured AdMeTech’s work and testimony.
January 2012: American College of Radiology (ACR) recognized AdMeTech’s research efforts in prostate MRI and established a formal partnership for the development of standards for high quality prostate MRI service and its transfer to patients.
Fiscal Year 2012: US President’s Budget highlighted molecular imaging of prostate cancer as one of the top national research priorities for the first time.
January 2012 – Present: AdMeTech’s-supported pioneering molecular imaging research at the Johns Hopkins University reported development of a novel approach to accurate diagnosis and treatment of prostate cancer (using optical and PET technologies), which is currently undergoing clinical evaluation.
May 2012: Both the House Armed Services Committee and the House Appropriations Committee supported AdMeTech’s “Where Is Our Manogram?” public awareness and advocacy campaign by directing Department of Defense to prioritize research funding for the advancement of prostate imaging in their Reports accompanying the National Defense Authorization Act and the Defense Appropriation Bill for fiscal year 2013.
June 14, 2012: Senator John Kerry (D-MA) issued a bipartisan Prostate Cancer Resolution (S. Res. 493), which acknowledged prostate cancer in African-American men as a health care crisis and urged Federal agencies to support research for the advancement of early detection, including biomarkers and imaging technologies. This legislation passed on July 26, 2012.
June 27, 2012: Senator Barbara Boxer (D-CA) in cooperation with Senator Kerry in the US Senate and Representative Elijah E. Cummings (D-MD) in the US House of Representatives introduced the bipartisan Prostate Cancer Detection Research and Education Act, which would have authorized $180 million in federal funding for research and education to improve early detection of prostate cancer.
June 28, 2012: AdMeTech Hosts Massachusetts State House Prostate Cancer Awareness Day featuring Senators John Kerry (D-MA) and Scott Brown (R-MA) by video, State Senate President, Speaker of the House, and more than 20 other key leaders of legislation, advocacy and medicine. These leaders had sent a petition to the Massachusetts Delegation in US Congress in support of the Boxer/Cummings Authorization Act. The prostate cancer advocacy groups participating in this event provided national leadership in formally endorsing this legislation, and were joined by six other national advocacy and medical associations from academia and industry.
July – October 2012: AdMeTech Foundation leads development of the conclusive multi-center clinical trial of prostate MRI, which is expected to have a groundbreaking impact on early detection of aggressive disease and elimination of unnecessary biopsies and treatment.
February 2013: AdMeTech Foundation holds a landmark awareness and fundraising event Dance for a Cure of Prostate Cancer featuring celebrity supporters from the ABC TV Dancing with the Stars, attracting nearly 600 attendees and coverage from Boston’s major media, and raising $100,000.
Click to close.
